AN
ANIK
—
Nasdaq
Biotechnology
Anika Therapeutics, Inc.
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
278,0M USD
P/E
—
EV / Rev
1,2x
Div yield
—
Op margin
-9,8 %
ROE
-7,9 %
Net margin
-9,6 %
Debt / equity
—
Beta
—
52w range
—
Volume
—
Day range
—
Prev close
$16,17
Open
—
Next earnings
2026-10-28
Ex-dividend
—
TR 1Y
—
About
Anika Therapeutics, Inc. is a medical device company that generates revenue through the sale of medical equipment and supplies, primarily within the healthcare sector.
Business. Anika Therapeutics, Inc. (Nasdaq: ANIK) is a biotechnology company operating within the Health Care sector. The firm generates revenue through the sale of products. Headquarters and specific operating segment or geographic details are not provided in the available data. The company is primarily listed on the Nasdaq stock exchange.
Classification85 %
SectorHealth Care
Industry groupBiotechnology
Generated · model-assisted
Sell-side consensus
BUY2 analysts
2 buy0 hold0 sell
Avg 12m price target19,00
Analyst recommendations
2 analysts · consensus BuyBuy2
Hold0
Sell0
12-month price target
19,00
Consensus of sell-side coverage.
At a glance
Score
—
not yet scored
Valuation
—
valuation pending
Analysts→
Buy
2 analysts · indicative
Ownership→
AQR Capital Management, LLC
largest disclosed fund holder
Profitability→
-7,9 %
return on equity
Quality
—
not yet scored
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
— missing data
News & coverage
0Sector rotation
Sector1D1Mvs mkt
Materials+2,3 %+6,6 %+1,7 %
Communication Services+2,2 %−5,5 %+1,6 %
Energy+0,6 %+3,3 %+0,0 %
Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
Information Technology+0,6 %+6,7 %+0,0 %
Consumer Discretionary+0,4 %+7,6 %−0,2 %
Financials−0,3 %−2,8 %−0,9 %
Consumer Staples−0,4 %+2,5 %−1,0 %
Real Estate−0,7 %+10,9 %−1,3 %
Industrials−1,9 %−3,1 %−2,5 %
Utilities−1,9 %+28,2 %−2,5 %
Developing storylines
No tracked sagas currently linked to ANIK. Browse all sagas →
Analysis
AI analysis
Generated · analysis pipeline · tier hybrid · as of 2026-08-04
↑ At a glance
Opportunity
— missing data
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
— missing data
Signals & dispatch
peak dispatch · —
Composite-score breakdown
Synthesis
Business
Anika Therapeutics, Inc. (Nasdaq: ANIK) is a biotechnology company operating within the Health Care sector. The firm generates revenue through the sale of products. Headquarters and specific operating segment or geographic details are not provided in the available data. The company is primarily listed on the Nasdaq stock exchange.
Classification85 %
SectorHealth Care
Industry groupBiotechnology
AI synthesis
GENERATEDAnika Therapeutics maintains a debt-free capital structure with a debt-to-equity ratio of 0.0 and a robust current ratio of 4.48, indicating strong short-term liquidity coverage. The company holds $38.4 million in cash and equivalents against total assets of $183.5 million and total equity of $137.3 million. Despite this balance sheet strength, the firm generated negative operating cash flow of -$5.5 million and negative free cash flow of -$8.4 million in Q2 2026, driven by a net loss of $1.7 million and significant share repurchases totaling $9.5 million in the period. The cash burn rate is partially offset by interest income and non-cash adjustments, but the negative free cash flow highlights ongoing operational cash consumption.
Profitability metrics remain negative, with a return on equity of -7.93% and a return on assets of -5.93%, reflecting the company's current loss-making status. The gross profit of $40.2 million on revenue of $62.2 million suggests a gross margin of approximately 64.7%, which is typical for specialized medical device manufacturers, but operating expenses exceed gross profit, resulting in an operating loss of $2.5 million. The company does not have cohort median data provided for direct comparison, but the negative returns indicate that the business is not yet generating positive economic returns on its invested capital. The high stock-based compensation expense of $8.5 million in the first half of 2026 further pressures operating income, although it is a non-cash charge.
Key takeaways
- Anika Therapeutics maintains a debt-free balance sheet with a strong current ratio of 4.48, but generates negative free cash flow of -$8.4 million in Q2 2026.
- The company reported a net loss of $1.7 million in Q2 2026, an improvement from the $8.8 million loss in the same period in 2025, driven by operational efficiencies and reduced losses.
- Inventory levels have increased significantly to $31.1 million, with raw materials and work-in-process growing, suggesting potential future production or sales cycles.
- Analyst sentiment is positive, with a mean price target of $19.00 and a mean recommendation of 1.50, indicating expectations for future growth and profitability.
- The company engaged in significant share repurchases of $9.5 million in the first half of 2026, demonstrating management's confidence in the company's long-term value.
- Risk factors include the need for sales growth to manage operational expansion and the potential for inventory write-downs if demand does not meet expectations.
Bull / Bear case
Generated · model-assistedBULL CASE · 3
Analysts assign a strong buy rating with a mean price target of $19.00, implying 29.5% upside from the current market price.
The company maintains a debt-to-equity ratio of 0.0, indicating a low leverage band and minimal financial risk from debt obligations.
Low dilution and liquidity risk flags suggest stable capital structure and adequate access to funds for ongoing operations and growth.
BEAR CASE · 2
Revenue declined at a two-year CAGR of 15.2% from FY2023 to FY2025, signaling a persistent contraction in top-line growth.
Cash conversion ratio of -1.03 places the company in the bottom quartile of the biotechnology cohort, reflecting poor cash generation efficiency.
In focus — financials by report
Quarterly
Annual
QUARTERLYFiled 2026-06-30
Q1 2026 · Quarter highlights
Revenue $62.2M; Operating income -$2.5M.
Revenue$62.2M
Operating income-$2.5M
Net income-$1.7M
Free cash flow-$8.4M
EPS—
Operating cash flow-$5.5M
Financials
Income statement
Revenue$62.2M
Gross profit$40.2M
Operating income-$2.5M
Net income-$1.7M
Margins
Gross margin64.7%
Operating margin-4.1%
Net margin-2.8%
FCF margin-13.5%
Balance sheet
Total assets$183.5M
Total liabilities—
Total equity$137.3M
Cash & equivalents$38.4M
Long-term debt—
Cash flow
Operating cash flow-$5.5M
CapEx$2.9M
Free cash flow-$8.4M
SBC$8.5M
P&L flow · revenue → net income
Highlights
- ▍Revenue $62.2M
- ▍Operating income -$2.5M
- ▍Net margin -2.8%
QUARTERLYFiled 2026-03-31
Q4 2025 · Quarter highlights
Revenue $29.6M; Operating income -$5.5M.
Revenue$29.6M
Operating income-$5.5M
Net income-$5.1M
Free cash flow-$6.3M
EPS—
Operating cash flow-$4.8M
Financials
Income statement
Revenue$29.6M
Gross profit$19.0M
Operating income-$5.5M
Net income-$5.1M
Margins
Gross margin64.2%
Operating margin-18.5%
Net margin-17.1%
FCF margin-21.2%
Balance sheet
Total assets$179.4M
Total liabilities—
Total equity$133.9M
Cash & equivalents$41.0M
Long-term debt—
Cash flow
Operating cash flow-$4.8M
CapEx$1.4M
Free cash flow-$6.3M
SBC$6.6M
P&L flow · revenue → net income
Highlights
- ▍Revenue $29.6M
- ▍Operating income -$5.5M
- ▍Net margin -17.1%
QUARTERLYFiled 2026-03-31
Q4 2025 · Quarter highlights
Revenue—
Operating income—
Net income-$5.1M
Free cash flow—
EPS—
Operating cash flow—
Financials
Income statement
Revenue—
Gross profit—
Operating income—
Net income-$5.1M
Balance sheet
Total assets—
Total liabilities—
Total equity$133.9M
Cash & equivalents—
Long-term debt—
ANNUALFiled 2025-12-31
FY 2025 · Full-year highlights
Revenue $112.8M; Operating income -$11.1M.
Revenue$112.8M
Operating income-$11.1M
Net income-$10.9M
Free cash flow$4.4M
EPS—
Operating cash flow$11.2M
Financials
Income statement
Revenue$112.8M
Gross profit$63.8M
Operating income-$11.1M
Net income-$10.9M
Margins
Gross margin56.6%
Operating margin-9.8%
Net margin-9.6%
FCF margin3.9%
Balance sheet
Total assets$190.3M
Total liabilities—
Total equity$143.5M
Cash & equivalents$57.5M
Long-term debt—
Cash flow
Operating cash flow$11.2M
CapEx$6.8M
Free cash flow$4.4M
SBC$10.1M
P&L flow · revenue → net income
Highlights
- ▍Revenue $112.8M
- ▍Operating income -$11.1M
- ▍Net margin -9.6%
ANNUALFiled 2024-12-31
FY 2024 · Full-year highlights
Revenue $119.9M; Operating income -$5.1M.
Revenue$119.9M
Operating income-$5.1M
Net income-$56.4M
Free cash flow-$2.3M
EPS—
Operating cash flow$5.4M
Financials
Income statement
Revenue$119.9M
Gross profit$76.0M
Operating income-$5.1M
Net income-$56.4M
Margins
Gross margin63.4%
Operating margin-4.3%
Net margin-47.0%
FCF margin-1.9%
Balance sheet
Total assets$202.7M
Total liabilities—
Total equity$154.0M
Cash & equivalents$55.6M
Long-term debt—
Cash flow
Operating cash flow$5.4M
CapEx$7.7M
Free cash flow-$2.3M
SBC$13.1M
P&L flow · revenue → net income
Highlights
- ▍Revenue $119.9M
- ▍Operating income -$5.1M
- ▍Net margin -47.0%
ANNUALFiled 2024-12-31
FY 2025 · Full-year highlights
Revenue $119.9M; Operating income -$5.1M.
Revenue$119.9M
Operating income-$5.1M
Net income-$56.4M
Free cash flow-$2.3M
EPS—
Operating cash flow$5.4M
Financials
Income statement
Revenue$119.9M
Gross profit$76.0M
Operating income-$5.1M
Net income-$56.4M
Margins
Gross margin63.4%
Operating margin-4.3%
Net margin-47.0%
FCF margin-1.9%
Balance sheet
Total assets$202.7M
Total liabilities—
Total equity$154.0M
Cash & equivalents$55.6M
Long-term debt—
Cash flow
Operating cash flow$5.4M
CapEx$7.7M
Free cash flow-$2.3M
SBC$13.1M
P&L flow · revenue → net income
Highlights
- ▍Revenue $119.9M
- ▍Operating income -$5.1M
- ▍Net margin -47.0%
ANNUALFiled 2023-12-31
FY 2023 · Full-year highlights
Revenue $166.7M; Operating income -$87.6M.
Revenue$166.7M
Operating income-$87.6M
Net income-$82.7M
Free cash flow-$7.2M
EPS—
Operating cash flow-$1.8M
Financials
Income statement
Revenue$166.7M
Gross profit$103.1M
Operating income-$87.6M
Net income-$82.7M
Margins
Gross margin61.9%
Operating margin-52.6%
Net margin-49.6%
FCF margin-4.3%
Balance sheet
Total assets$270.6M
Total liabilities—
Total equity$212.3M
Cash & equivalents$72.9M
Long-term debt—
Cash flow
Operating cash flow-$1.8M
CapEx$5.4M
Free cash flow-$7.2M
SBC$15.2M
P&L flow · revenue → net income
Highlights
- ▍Revenue $166.7M
- ▍Operating income -$87.6M
- ▍Net margin -49.6%
ANNUALFiled 2023-12-31
FY 2024 · Full-year highlights
Revenue $120.8M; Operating income $844.0k.
Revenue$120.8M
Operating income$844.0k
Net income-$82.7M
Free cash flow-$7.2M
EPS—
Operating cash flow-$1.8M
Financials
Income statement
Revenue$120.8M
Gross profit$82.5M
Operating income$844.0k
Net income-$82.7M
Margins
Gross margin68.3%
Operating margin0.7%
Net margin-68.4%
FCF margin-6.0%
Balance sheet
Total assets$270.6M
Total liabilities—
Total equity$212.3M
Cash & equivalents$68.7M
Long-term debt—
Cash flow
Operating cash flow-$1.8M
CapEx$5.4M
Free cash flow-$7.2M
SBC$15.2M
P&L flow · revenue → net income
Highlights
- ▍Revenue $120.8M
- ▍Operating income $844.0k
- ▍Net margin -68.4%
Valuation FY
Market price
$20,70
Market cap
$197.0M
Enterprise valueⓘ
$132.8M
P/Eⓘ
—
Non-GAAP P/Eⓘ
—
EV / Revenueⓘ
1.2x
EV / Op incomeⓘ
—
EV / OCFⓘ
11.9x
P / Bⓘ
—
P / Tangible bookⓘ
—
Tangible book
—
Net cashⓘ
$64.2M
Current ratioⓘ
4.5
Debt / equityⓘ
—
ROAⓘ
-5.9%
ROEⓘ
-7.9%
Cash conversionⓘ
-103.0%
CapEx / revenueⓘ
6.0%
SBC / revenueⓘ
8.9%
Dilution ratioⓘ
0.4%
Revenue by segment
Business relationships
Business relationships2 disclosed relationships · 1 type · extracted from filings & disclosures
Customers2
Johnson & JohnsonJNJ.NCustomer95%Source ↗
ANON:CUST:ANIK.O:JJMedTechANON:CUST:ANIK.O:JJMedTechCustomer88%Source ↗
Supply chain
Vendors → ANIK ↔ Partners → Customers · click any node to drill
2 mentions in 10-K0 from corporate websites0 from news dispatches
Updated 2026-07-04Peer comparison
— missing data
Market position
Stress test
— missing data
Predictor forecast
Next quarternear-term
Earnings · next quarterconf 69 %
EPS
Consensus EPS
0,21
Predicted surprise
-0,08
Beat probability
69 %
Analysts
2
Other metrics
Revenue
—
no estimate
Segment revenue
—
no estimate
Margin
—
no estimate
Segment margin
—
no estimate
revision ratio 2,75 · as of 2026-07-30 · Earnings Surprise V1
Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
Full fiscal year~1 year ahead
Full fiscal year · our forecast vs guidance vs consensus
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | 0,21 |
| Revenue | —no estimate | —no estimate | 120,3M USD |
| Operating income | —no estimate | —no estimate | -12,2M USD |
Full-year consensus mean (period as reported by source) · consensus in USD. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
Probabilistic model output — not investment advice. · generated 2026-08-04
Options
— missing data
Short squeeze
— missing data
Earnings-call key lines
— missing data
Consensus distribution
sell-side coverageRecommendation distribution2 analysts
Strong buy1
Buy1
Hold0
Sell0
Strong sell0
12-month price target$19,00 · Median $19,00
Low $17,00High $21,00
Operating income · consensus-12,2M USD
EPS surprise
−461,9 %
reported vs consensus · miss
Revenue surprise
−6,2 %
reported vs consensus · miss
Estimate revisions
consensus EPS · 26-week trend— missing data
Sell-side observations
Low$17,00
Mean$19,00
Median$19,00
High$21,00
Spot$20,70
−8.2 %implied to mean12-month sell-side price targets · ▲ spot
Themes
— missing data
ESG
— missing data
Risk factors
Dilution riskLow
Liquidity riskLow
Filing-based flags
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Op Margin-9,8 %Above median
Net Margin-9,6 %Above median
ROE-7,9 %Above median
Capex / Rev6,0 %Above P75
D/E0,00Above median
Cash Conv-1,03Bottom quartile
Corporate actions / M&A
— missing data
FX exposure
— missing data
Comparable transactions
— missing data
Derivatives & instruments
Derivative transactions
Net acquired 357 317 sh11 exercises · 5 grants4 insiders
- Director, President and CEO · Restricted Stock Unit → Common StockDisposed 12 840exercise · 2026-06-03
- SVP, CAO & Treasurer · Premium Priced Stock Appreciation Rights → Common StockAcquired 17 663 @ $15,60grant · 2026-03-19
- SVP, CAO & Treasurer · Restricted Stock Unit → Common StockAcquired 11 194grant · 2026-03-19
- SVP, CAO & Treasurer · Restricted Stock Unit → Common StockAcquired 13 097grant · 2026-03-19
- EVP, General Counsel, Corp Sec · Restricted Stock Unit → Common StockDisposed 6 449exercise · 2026-03-15
- Director · Restricted Stock Unit → Common StockDisposed 25 131exercise · 2026-03-15
- SVP, CAO & Treasurer · Restricted Stock Unit → Common StockDisposed 2 658exercise · 2026-03-15
- Director · Restricted Stock Unit → Common StockDisposed 24 519exercise · 2026-03-14
- EVP, General Counsel, Corp Sec · Restricted Stock Unit → Common StockDisposed 9 388exercise · 2026-03-14
- Director, President and CEO · Restricted Stock Unit → Common StockDisposed 12 824exercise · 2026-03-14
- SVP, CAO & Treasurer · Restricted Stock Unit → Common StockDisposed 3 774exercise · 2026-03-14
- SVP, CAO & Treasurer · Restricted Stock Unit → Common StockDisposed 2 197exercise · 2026-03-09
- Director · Restricted Stock Unit → Common StockDisposed 20 001exercise · 2026-03-09
- EVP, General Counsel, Corp Sec · Restricted Stock Unit → Common StockDisposed 5 465exercise · 2026-03-09
- Director, President and CEO · Stock Appreciation Rights → Common StockAcquired 310 207 @ $9,23grant · 2026-02-01
- Director, President and CEO · Restricted Stock Unit → Common StockAcquired 130 402grant · 2026-02-01
Actions
Ask Handelsavisen
— missing data
Data sources
- Market data
- Regulatory filings
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Reference data
How metrics are computed
- Cash Conversion Ratiooperating_cash_flow / net_income
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Ev To Revenueenterprise_value / revenue
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Return On Equitynet_income / total_equity
- Market Capmarket_price * shares_outstanding_diluted
Source documents
- Anika Therapeutics, Inc. company facts · 2026-07-30
- Anika Therapeutics, Inc. 10-Q 2026-07-29 · 2026-07-30
- Anika Therapeutics, Inc. 10-Q 2026-04-30 · 2026-07-30
- Anika Therapeutics, Inc. 10-K 2026-03-03 · 2026-07-30
- Anika Therapeutics, Inc. 10-Q 2025-11-05 · 2026-07-30
- 8-K (sec_8k_material) on ANIK · 2026-07-30
- Anika Therapeutics Inc Market data — analyst estimates · 2026-07-30
- Anika Therapeutics Inc Market data — ESG · 2026-07-30
- Anika Therapeutics, Inc. HA canonical relationships · 2026-07-30
Ownership & reference
Top holders
- Investment Managers · as of 2026-03-310,00 %$4M
- Investment Managers · as of 2026-03-310,00 %$7M
- Investment Managers · as of 2026-03-310,00 %$2M
- Investment Managers · as of 2024-06-300,00 %$41M
- Investment Managers · as of 2026-03-310,00 %$13M
- Investment Managers · as of 2026-03-310,00 %$3M
- Institutional Investor · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$2M
- Investment Managers · as of 2026-03-310,00 %$5M
- Investment Managers · as of 2026-03-310,00 %$2M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$2M
- Investment Managers · as of 2024-12-310,00 %$1M
- Institutional Investor · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$5M
- Investment Managers · as of 2025-12-310,00 %$7M
- Institutional Investor · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$0M
- Funds · as of 2026-03-310,00 %$0M
- Institutional Investor · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$0M
- Brokerage Firms · as of 2026-03-310,00 %$0M
- Institutional Investor · as of 2026-03-310,00 %$0M
Leadership
- Stephen D. GriffinPresident, Chief Executive Officer, Director
Insider activity
Net buying2 buys · 0 sellsnet $223K9 insiders · last 365d
- Director · Common StockOther 10 402 · 2026-06-18
- Director · Common StockOther 10 402 · 2026-06-18
- Director · Common StockOther 10 402 · 2026-06-18
- Director · Common StockOther 10 402 · 2026-06-18
- Director · Common StockOther 10 402 · 2026-06-18
- Director, President and CEO · Common StockOther 12 840 · 2026-06-03
- Director, President and CEO · Common StockOther 3 769 @ $14,41$54K · 2026-06-03
- Director · Common StockBought 5 000 @ $14,66$73K · 2026-05-01
- Director, President and CEO · Common StockBought 12 200 @ $12,29$150K · 2026-04-30
- SVP, CAO & Treasurer · Common StockOther 2 658 · 2026-03-15
- EVP, General Counsel, Corp Sec · Common StockOther 6 449 · 2026-03-15
- EVP, General Counsel, Corp Sec · Common StockOther 1 893 @ $14,20$27K · 2026-03-15
- Director · Common StockOther 12 104 @ $14,20$172K · 2026-03-15
- SVP, CAO & Treasurer · Common StockOther 781 @ $14,20$11K · 2026-03-15
- Director · Common StockOther 25 131 · 2026-03-15
- Director, President and CEO · Common StockOther 6 412 · 2026-03-14
- EVP, General Counsel, Corp Sec · Common StockOther 9 388 · 2026-03-14
- EVP, General Counsel, Corp Sec · Common StockOther 4 694 · 2026-03-14
- EVP, General Counsel, Corp Sec · Common StockOther 4 168 @ $14,20$59K · 2026-03-14
- Director, President and CEO · Common StockOther 12 824 · 2026-03-14
- Director, President and CEO · Common StockOther 5 944 @ $14,20$84K · 2026-03-14
- Director · Common StockOther 24 519 · 2026-03-14
- Director · Common StockOther 24 520 · 2026-03-14
- Director · Common StockOther 14 728 @ $14,20$209K · 2026-03-14
- SVP, CAO & Treasurer · Common StockOther 3 774 · 2026-03-14
Short positioning
349.8Kshares short-16.1% vs prior
4.64days to cover
26.9%short of daily vol
92fails-to-deliver
as of 2026-07-15 · short-interest report (free)
Geographic breakdown
— missing data
Listings · one canonical issuer
all listings resolve to the canonical
ANIKCanonical
Nasdaq · USD
Intel & risk
peak dispatch · —
OSINT findings
Dilution riskLow
Liquidity riskLow
No immediate filing-based liquidity or dilution flags were detected.
Relationship graph
This companySectorCustomers
Evidence & claims
From filings & derived data- Revenue (annual): USD 112.82MUnknown
- Cash & equivalents (annual): USD 57.48MUnknown
- Current assets (annual): USD 103.36MUnknown
- Net income (annual): USD -11MUnknown
- EPS (diluted) (annual): USD-PER-SHARES -1Unknown
- EPS (basic) (annual): USD-PER-SHARES -1Unknown
- Current liabilities (annual): USD 21.91MUnknown
- Capex (annual): USD 6.83MUnknown
- Shares outstanding (annual): 13.89MUnknown
- Cost of revenue (annual): USD 49.01MUnknown
- Total assets (annual): USD 190.27MUnknown
- Operating income (annual): USD -11.05MUnknown
- R&D expense (annual): USD 25.77MUnknown
- Gross profit (annual): USD 63.81MUnknown
- Pre-tax income (annual): USD -9.31MUnknown
- Operating cash flow (annual): USD 11.19MUnknown
- Shareholders' equity (annual): USD 143.47MUnknown
- Pre-tax income (annual): USD -2.76MUnknown
- R&D expense (annual): USD 25.54MUnknown
- Gross profit (annual): USD 76MUnknown
- Revenue (annual): USD 119.91MUnknown
- Cash & equivalents (annual): USD 55.63MUnknown
- Capex (annual): USD 7.73MUnknown
- Current liabilities (annual): USD 23.31MUnknown
Showing 24 of 34 surfaced claims.
Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.
The Thread
Everything we know, in order2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date
2026-07-30 04:36 UTCFILINGMaterial 8-K
2026-06-30EARNINGSQuarterly results — Q1 2026 Revenue USD 62.2M · Net USD -1.7M
2026-06-18 00:00 UTCINSIDER8 insider transactions — 2026-06 1 derivative
2026-06-18 00:00 UTCINSIDER8 insider transactions — 2026-06 1 derivative
2026-06-18INSIDERHENNEMAN JOHN B III transacted 10.4k sh — Director
2026-06-18INSIDERCONLEY SHERYL L transacted 10.4k sh — Director
2026-06-18INSIDERCapper Joseph H transacted 10.4k sh — Director
2026-06-18INSIDERRichard Stephen transacted 10.4k sh — Director
2026-06-18INSIDERFischetti Gary P transacted 10.4k sh — Director
2026-06-03INSIDERGriffin Stephen D. transacted 12.8k sh — Director, President and CEO
2026-06-03INSIDERGriffin Stephen D. transacted 3.8k sh — Director, President and CEO ~$54k
2026-06-03INSIDERGriffin Stephen D. disposed of 12.8k sh Restricted Stock Unit — Director, President and CEO
2026-05-01 00:00 UTCINSIDER1 insider transaction — 2026-05
2026-05-01 00:00 UTCINSIDER1 insider transaction — 2026-05
2026-05-01INSIDERHENNEMAN JOHN B III bought 5.0k sh — Director ~$73k
2026-04-30 00:00 UTCINSIDER1 insider transaction — 2026-04 · net buy $150k
2026-04-30 00:00 UTCINSIDER1 insider transaction — 2026-04 · net buy $150k
2026-04-30INSIDERGriffin Stephen D. bought 12.2k sh — Director, President and CEO ~$150k
2026-03-31EARNINGSQuarterly results — Q4 2025 Revenue USD 29.6M · Net USD -5.1M
2026-03-31EARNINGSQuarterly results — Q4 2025 Net USD -5.1M
2026-03-19 00:00 UTCINSIDER37 insider transactions — 2026-03 · net sell $709k 13 derivative
2026-03-19 00:00 UTCINSIDER37 insider transactions — 2026-03 · net sell $709k 13 derivative
2026-03-19INSIDERMcLeod Ian acquired 13.1k sh Restricted Stock Unit — SVP, CAO & Treasurer
2026-03-19INSIDERMcLeod Ian acquired 17.7k sh Premium Priced Stock Appreciation Rights — SVP, CAO & Treasurer
2026-03-19INSIDERMcLeod Ian acquired 11.2k sh Restricted Stock Unit — SVP, CAO & Treasurer
2026-03-15INSIDERMcLeod Ian transacted 2.7k sh — SVP, CAO & Treasurer
2026-03-15INSIDERColleran David transacted 6.4k sh — EVP, General Counsel, Corp Sec
2026-03-15INSIDERColleran David transacted 1.9k sh — EVP, General Counsel, Corp Sec ~$27k
2026-03-15INSIDERBlanchard Cheryl R transacted 12.1k sh — Director ~$172k
2026-03-15INSIDERMcLeod Ian transacted 781 sh — SVP, CAO & Treasurer ~$11k
2026-03-15INSIDERBlanchard Cheryl R transacted 25.1k sh — Director
2026-03-15INSIDERBlanchard Cheryl R disposed of 25.1k sh Restricted Stock Unit — Director
2026-03-15INSIDERColleran David disposed of 6.4k sh Restricted Stock Unit — EVP, General Counsel, Corp Sec
2026-03-15INSIDERMcLeod Ian disposed of 2.7k sh Restricted Stock Unit — SVP, CAO & Treasurer
2026-03-14INSIDERGriffin Stephen D. transacted 6.4k sh — Director, President and CEO
2026-03-14INSIDERColleran David transacted 9.4k sh — EVP, General Counsel, Corp Sec
Showing the 40 most recent of 69 entries.
The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04
Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data · Reference data
Premium coverage